Evidity Health Capital
VC Fund
New York, United States
Evidity Health Capital is a VC fund in New York focused on Health Care and Medical Device. Evidity Health Capital, formerly known as Canepa Healthcare, specializes in medical devices, in vitro diagnostics, and disruptive digital health. We focus on private companies with commercialized products that need growth capital to achieve profitability.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Evidity Health Capital invests in
Stages Evidity Health Capital invests in
Countries Evidity Health Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alejandro Sanchez
|
|||
Paul Enever
|
|||
Adam Lessler
|
|||
Investment Focus
Industry
- Health Care 12 (60%)
- Medical Device 8 (40%)
- Medical 5 (25%)
- Biotechnology 5 (25%)
- Health Diagnostics 3 (15%)
Stage
- Series D 4 (20%)
- Funding Round 4 (20%)
- Series C 3 (15%)
- Series B 2 (10%)
- Series A 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Alejandro Sanchez
Managing Director
|
Managing Director | Total investments: 2 | Find email | |
|
Paul Enever
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
|
Adam Lessler
Principal
|
Principal | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
GT Medical Technologies
|
GT Medical Technologies is a medical technology company focused on improving outcomes for patients with brain tumors through treatment solutions. It was established by to address unmet needs in neuro-oncology and advance the standard of care for patients with operable brain tumors. The company's flagship product, GammaTile®, is an FDA-cleared,bioabsorbable collagen implant embedded with radiation seeds that delivers targeted radiation therapy directly to the surgical cavity immediately following tumor removal. By providing localized treatment at the time of surgery, GammaTile is designed to target residual cancer cells while reducing radiation exposure to surrounding healthy brain tissue. This approach aims to help prevent tumor recurrence and improve patient outcomes. | $100M / Series E / Jun 09, 2026 | |
GT Medical Technologies
|
GT Medical Technologies, Inc. (GT), an Arizona-based medical device company, is focused on improving the lives of patients with brain tumors. GT has developed an innovative approach to treatment by combining a conformable collagen matrix with brachytherapy (radiation) seeds. The company's first product, GammaTile™ is protected by 10 US and 2Canadian issued patents, and 1 EPO patent. The product has the promise to revolutionize treatment for 176,000 patients/year in the US alone. To date, we have treated 120 patients with recurrent brain tumors in a clinical trial at Barrow Neurological Institute (BNI) and observed significant clinical improvement. | $53.3M / Series D / Jan 16, 2025 | |
Augmedics
|
Augmedics is a provider of augmented reality (AR) surgical image guidance solutions. Augmedics seeks to improve healthcare by developing cutting-edge technologies that will revolutionize surgical treatment. The company’s first product, the xvision-spine (XVS) system, is an augmented-reality surgical navigation system designed to allow surgeons tosee and navigate inside a patient’s body during complex procedures. | $82.5M / Series D / Jun 27, 2023 | |
Prelude
|
PreludeDx was founded with the goal of providing better decision-making tools to breast cancer patients and physicians. Founded in 2009 with technology licensed from the University of California San Francisco, PreludeDx has focused on developing breast cancer tools that will impact a patient’s treatment decision. Their mission is to provide toolsthat improve patient outcomes in breast cancer and reduce the overall cost burden to the healthcare system. | $20M / Venture - Series Unknown / Mar 22, 2022 | |
Magnolia Medical Technologies
|
Magnolia Medical Technologies is a device development company that focuses on improving the accuracy of diagnostic blood culture tests. It has developed a wide range of products to significantly improve diagnostic specimen quality aimed at directly and dramatically increasing diagnostic accuracy for critical laboratory tests. The company’sintellectual property portfolio includes more than 70 issued patents with more than 50 additional patent applications pending.It was incorporated in 2011 and is based in Seattle, Washington. | Feb 16, 2022 | |
|
Magnolia Medical Technologies
|
Magnolia Medical Technologies is a device development company that focuses on improving the accuracy of diagnostic blood culture tests. It has developed a wide range of products to significantly improve diagnostic specimen quality aimed at directly and dramatically increasing diagnostic accuracy for critical laboratory tests. The company’sintellectual property portfolio includes more than 70 issued patents with more than 50 additional patent applications pending.It was incorporated in 2011 and is based in Seattle, Washington. | $46M / Private Equity / Feb 16, 2022 | |
Akili Interactive Labs
|
Akili Interactive Labs their broad pipeline of programs to treat cognitive deficiency and improve symptoms associated with medical conditions across neurology and psychiatry, including attention-deficit hyperactivity and disorder (ADHD), major depressive disorder (MDD), autism spectrum disorder (ASD) and various inflammatory diseases. | $110M / Series D / May 26, 2021 | |
Sonde Health
|
Sonde Health is a digital medicine company developing voice-based technologies to transform the way we monitor and diagnose our mental and physical health. | $16M / Series A / Apr 11, 2019 | |
|
Magnolia Medical Technologies
|
Magnolia Medical Technologies is a device development company that focuses on improving the accuracy of diagnostic blood culture tests. It has developed a wide range of products to significantly improve diagnostic specimen quality aimed at directly and dramatically increasing diagnostic accuracy for critical laboratory tests. The company’sintellectual property portfolio includes more than 70 issued patents with more than 50 additional patent applications pending.It was incorporated in 2011 and is based in Seattle, Washington. | $20M / Series C / Jan 30, 2019 | |
EndoGastric Solutions
|
EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0procedure—a minimally invasive solution that addresses a significant unmet clinical need.EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington. | $40.6M / Series I / Jun 19, 2018 | |
| See all 20 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Evidity Health Capital invest in?
Evidity Health Capital invests primarily in Health Care, Medical Device and Medical startups, most often at Series D and Funding Round stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Evidity Health Capital?
Public channels for Evidity Health Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Evidity Health Capital?
The team at Evidity Health Capital includes Alejandro Sanchez (Managing Director), Paul Enever (Managing Director) and Adam Lessler (Principal). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
